Researchers found that the Drug Enforcement Administration (DEA) plans to classify certain concentrated and synthetic kratom-derived opioids as Schedule I controlled substances. This decision comes in response to the growing concern over the safety of kratom products, which are often marketed as natural remedies for energy, mood improvement, pain relief, anxiety reduction, and even opioid withdrawal management. However, these products have not received approval from the U.S. Food and Drug Administration (FDA) for any medical use, raising significant health concerns.

This classification matters for your health because it aims to prevent potential risks associated with kratom-derived opioids, which include dependence, addiction, respiratory depression, overdose, and even death. As these products become more popular, especially in forms like gummies and liquid shots, people may unknowingly expose themselves to dangerous substances. The Partnership for a Drug-Free New Jersey emphasizes that consumers often lack reliable information about the potency and purity of these products, which can lead to serious public health risks.

The DEA’s action is a proactive measure, but it’s important to note that this is an early-stage response to a growing issue. While the classification aims to curb the spread of these potentially harmful substances, the broader implications for public health and safety are still being evaluated. The Partnership for a Drug-Free New Jersey calls this move a critical first step in addressing the evolving marketplace of kratom-derived compounds. As consumers, being aware of the risks associated with unregulated products is essential for making informed choices about your health.

Source